Patients with chronic spontaneous urticaria experienced early symptom improvements that were sustained through 52 weeks with remibrutinib, according to a presentation at the European Academy of Allergy & Clinical Immunology Congress. The safety profile for the Bruton’s tyrosine kinase (BTK) inhibitor was favorable and consistent through 52 weeks as well, the researchers said.
CSU Can Affect All Aspects of Patients' Lives, Explained Dr Jonathan Bernstein ajmc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ajmc.com Daily Mail and Mail on Sunday newspapers.
– Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs – – Management to host conference call and.
Allakos reports disappointing topline data from phase 2 trials for lirentelimab in atopic dermatitis and chronic spontaneous urticaria. Company undergoes restructuring to focus on AK006, extending cash runway into mid-2026.